奥扎格雷联合低分子肝素钙治疗40例脑血栓的临床疗效分析

目的对奥扎格雷联合低分子肝素钙治疗脑血栓的临床治疗效果进行分析。方法抽取2010年9月-2012年2月期间患脑血栓的患者80例,随机分为对照组和改良组,每组各40例脑血栓患者。对对照组中的脑血栓患者进行低分子肝素钙治疗,而对改良组中的脑血栓患者在进行低分子肝素钙治疗的基础上加用奥扎格雷药物的使用。对两组患者的治疗效果情况进行了解,并且进行比较分析。结果对照组中有32例脑血栓患者治疗有效,占80.00%,而改良组中有40例脑血栓患者治疗有效,占100.00%,即相对于对照组,改良组中的脑血栓患者的治疗效果更为良好,不良反应程度较轻P〈0.05。结论对脑血栓患者进行疾病治疗时,选择在常规治疗的基础上加用奥扎格雷联合低分子肝素钙治疗,对于提高患者的疾病治疗效果有一定的意义。     

低分子肝素钙与肾炎康复片治疗原发性肾病综合征分析

目的 分析肾炎康复片联合低分子肝素钙对原发性肾病综合征疾病患者的临床治疗效果.方法 选择患有原发性肾病综合征疾病的患者82例,随机分为对照组和试验组,每组41例.对照组患者采用低分子肝素钙治疗;试验组患者采用肾炎康复片联合低分子肝素钙治疗.比较2组治疗效果.结果 试验组患者肾功能指标恢复正常时间(15.07±2.16)d和肾病药物治疗总时间(19.86±2.07)d明显短于对照组[(19.52±3.54)d、(23.68±3.10)d](P<0.05);原发性肾病综合征疾病药物治疗效果(总有效率90.3%)明显优于对照组(总有效率68.3%)(P<0.05);用药期间药物不良反应发生率(2.4%)明显低于对照组(22.0%)(P<0.05).结论 应用肾炎康复片与低分子肝素钙联合对患有原发性肾病综合征疾病的患者实施治疗的临床效果非常明显.     

奥扎格雷联合低分子肝素钙治疗脑血栓患者的疗效观察

目的:观察奥扎格雷联合低分子肝素钙治疗脑血栓患者的疗效。方法:回顾性分析176例脑血栓患者临床资料,依据给药方法的不同,分为研究组(83例)和对照组(93例)。对照组患者给予低分子肝素钙药物治疗;研究组患者在对照组基础上联合奥扎格雷药物治疗。治疗前后,比较两组患者的神经功能的缺损评分、血清GMP140、vWF水平及复发情况。结果:治疗后,研究组患者的神经功能的缺损评分、血清GMP140、vWF水平均优于对照组;研究组患者的复发率低于对照组(P<0.05)。结论:奥扎格雷联合低分子肝素钙治疗脑血栓患者的效果优于单纯低分子肝素钙。     

脑血栓治疗中奥扎格雷联合低分子肝素钙的应用效果观察

目的 观察奥扎格雷联合低分子肝素钙治疗脑血栓的临床效果.方法 将95例脑血栓患者作为研究对象,以不同的治疗方案将其随机分为2组,分别给予奥扎格雷治疗(对照组)和奥扎格雷联合低分子肝素钙治疗(治疗组),对2组临床效果、不良反应发生情况和神经功能缺损情况进行对比.结果 治疗组有效率高于对照组,不良反应发生率低于对照组,差异明显(P<0.05).治疗组的NIHSS评分也明显优于对照组,差异明显(P<0.05).结论 奥扎格雷联合低分子肝素钙治疗脑血栓可以有效溶解血栓、减轻临床症状,且安全性较高,值得临床推广.     

奥扎格雷治疗不稳定型心绞痛266例疗效观察

目的：观察奥扎格雷治疗不稳定心绞痛的临床疗效。方法：患者均为符合美国心脏病学院（ACC）和美国心脏病学会（AHA）诊断标准的UAP266例,其中奥扎格雷组141例,用奥扎格雷160mg/d,静脉滴注,1次/d,共14d。另对照组125例,用低分子肝素钙6 000U/d,1次/12h,共7d,两组均接受常规治疗。结果：两组治疗前、后心绞痛发作次数分别从（6±2）次/d和（7±2）次/d减少至（1±0.5）次/d和（1±0.7）次/d,（P〈0.01）;常规心电图ST段压低或提高分别从（3.0±0.5）mm和（3.0±0.9）mm恢复到（1.0±0.5）mm和（1.3±0.5）mm,（P〈0.05）。奥扎格雷、低分子肝素钙对血小板计数均无显著影响,奥扎格雷组无出血表现,低分子肝素钙组有36例出现皮下淤斑。结论：奥扎格雷和低分子肝素钙对不稳定心绞痛均有较好临床疗效,但奥扎格雷出血不良反应更少。     

低分子肝素联合奥扎格雷治疗脑血栓形成的临床效果分析

目的探讨低分子肝素联合奥扎格雷治疗脑血栓形成的临床效果。方法将2012年9月至2015年9月鄢陵县中医院收治的150例脑血栓形成患者随机分成对照组与观察组,每组75例,对照组给予奥扎格雷治疗,观察组给予低分子肝素联合奥扎格雷治疗,观察两组患者的临床疗效以及不良反应。结果观察组总有效率高于对照组,差异具有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论低分子肝素联合奥扎格雷治疗脑血栓形成的临床效果显著,能够明显改善患者神经功能,值得推广应用。     

奥扎格雷联合低分子肝素钙治疗急性进展性脑梗死48例

目的观察奥扎格雷联合低分子肝素钙治疗急性进展性脑梗死的疗效及安全性。方法将96例急性进展性脑梗死患者随机分为对照组与治疗组,每组48例。对照组采用血栓通、小剂量阿司匹林等常规治疗,治疗组在此基础上加用奥扎格雷80mg,2次／d,静脉滴注,连用14d,低分子肝素钙2500U,2次／d,皮下注射,连用10d。治疗前及治疗2周后对两组患者的血小板、凝血四项及临床神经功能缺损程度评分（NDS）进行评定。结果治疗组临床显效率（75％）明显优于对照组（37．5％）（P〈0．01）;治疗组治疗后NDS为（5．2±4．6）分,明显低于对照组的（13±9）分（P〈0．01）;血小板、凝血酶原时间均在正常范围内,两组均无明显不良反应。结论奥扎格雷联合低分子肝素钙治疗急性进展性脑梗死安全有效．值得临床推广。     

低分子肝素钙与奥扎格雷钠联合治疗播散性血管内凝血的临床观察

目的探讨低分子肝素钙与奥扎格雷钠联合使用对播散性血管内凝血的治疗效果。方法：17例患者使用低分子肝素钙加奥扎格雷钠，18例使用普通肝素治疗。结果治疗组的总有效率（82．4％）高于对照组（66．7％），有显著性差异（P〈0.05）。结论低分子肝素钙与奥扎格雷钠联合使用冶疗播散性血管内凝血疗效显著。     

奥扎格雷联合低分子肝素钙对脑血栓的效果及不良反应发生率分析

目的 探讨奥扎格雷联合低分子肝素钙治疗脑血栓的临床效果.方法 选取2018年5月-2020年5月收治的70例脑血栓患者,按照用药方案的不同将其分为对照组(低分子肝素钙,35例)与观察组(奥扎格雷联合低分子肝素钙,35例).对比2组患者治疗前后的神经功能缺损状况[美国国立卫生研究院卒中量表(NIHSS)评分]、凝血功能指...     

低分子肝素钙联合奥扎格雷钠治疗不稳定型心绞痛

目的 探讨低分子肝素钙联合奥扎格雷钠治疗不稳定型心绞痛的临床疗效及作用机制.方法 将64例不稳定型心绞痛(UAP)患者随机分为治疗组(低分子肝素钙+奥扎格雷钠+阿司匹林)和对照组(低分子肝素钙+阿司匹林),疗程7 d,随诊14 d,治疗前后监测心电图改变及血液流变学、心绞痛发作次数和时间、心血管事件.结果 治疗组总有效率93.7%,对照组总有效率81.2%,治疗组未发现明显不良反应,疗效优于对照组(P＜0.05).结论 低分子肝素钙联合奥扎格雷钠对不稳定型心绞痛疗效好,可有效控制心绞痛发作,减少心血管事件发生.     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Expression of OPGmRNA and ODFmRNA in the patients of hip fracture due to osteoporosis

Objective：To investigate the gene expression of osteoprotegerin（OPG） and osteoclast differentiation factor（ODF） in the bone tissue of patients with hip fracture due to osteoporosis. Methods：OPGmRNA and ODFmRNA in the bone tissue in 50 cases of osteoporosis sufferers（over 50 years old） with hip fracture（Observer Group） and 30 cases of hip facture sufferers with no osteoporosis（Control group） were analyzed with the Semi-Quantitative RT-PCR method. Results：The mRNA expressed of ODF, OPG were both high in the patients with hip fracture. In the control group, the expression of OPG mRNA was observed, while the expression of ODF mRNA was very slight. Conclusion：Aged patients contained all signals including OPG, ODF that are essential for inducing osteoclastogenesis and promoting bone resorption.     

The clinicopathological and immuohistochemical analysis of solid-pseudopapillary tumor of the pancreas： report of 9 cases

Objective：To investigate the clinical features, pathological characteristics and immunophenotype of solid-pseudopapillary tumor of the pancreas（SPTP）. Methods：Nine surgically treated cases of SPTP were retrospectively reviewed. Hematoxylin and Eosin（HE） staining and immunohistochemical staining were used to analyze all cases, and the general clinical data was collected. Results：Six patients were asymptomatic except for a palpable mass. Two patients complained of vague-epigastric pain. One patient appeared jaundice. The tumor was encapsulated and solid tissues alternately with cystic tissues. Histologically, the histological structure of solid portion was pseudopapillary with a fibrovascular core. Tumor cells were uniform and medium-sized which were arranged in sheets ets or nests or pseudopapillary patterns. Immunohistochemical studies demonstrated that SPTP proved positive in vimentin（9/9 cases）, AAT（9/9 cases）, NSE（9/9 cases）, ACT（7/9 cases）, CK20（2/9 cases）, CgA（1/9 cases）, S-100（3/gcases）, PR（4/gcases）, Syn（3/9 cases） and CD56（5/9cases）, negative in CEA and ER. Conclusion：SPTP is a tumor predominantly occurring in young women frequently without special symptoms. This tumor has various characteristical histological patterns with different immunophenotype.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

Luo Lingjie's Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Dr.Zhang Ren's Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.